Impact of Smoking Status on the Efficacy of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: a Systematic Review

Overview

Journal BMJ Open

Specialty General Medicine

Date 2020 Apr 18

PMID 32300001

Citations 10

Authors

Kimberley Sonnex

Hanna Alleemudder

Roger Knaggs

Affiliations

Soon will be listed here.

Abstract

Objectives: Inhaled corticosteroids (ICS) reduce exacerbation rates and the decline in lung function in people with chronic obstructive pulmonary disease (COPD). There is evidence that smoking causes 'steroid resistance' and thus reduces the effect of ICS. This systematic review aimed to investigate the effect of smoking on efficacy of ICS in COPD in terms of lung function and exacerbation rates.

Design: Systematic review.

Data Sources: An electronic database search of PubMed, Ovid MEDLINE, Ovid Embase and Cochrane Library (January 2000 to January 2020).

Eligibility Criteria: Fully published randomised controlled trials (RCTs), in the English language, evaluating the use of ICS in COPD adults that stratified the participants by smoking status. Trials that included participants with asthma, lung cancer and pneumonia were excluded. The primary outcome measures were changes in lung function and yearly exacerbation rates.

Data Extraction And Synthesis: Two independent reviewers extracted data and assessed risk of bias using the Cochrane Collaboration's tool.

Results: Seven studies were identified. Four trials (17 892 participants) recorded change in forced expiratory volume in one second (FEV) from baseline to up to 30 months after starting treatment. Heavier smokers (>36 pack years) using ICS had a greater decline in FEV that ranged from -22 mL to -75 mL in comparison to lighter smokers. Smokers using ICS had mixed results in FEV change: -8 mL to +77 mL in comparison to ex-smokers. Four trials (21 270 participants) recorded difference in COPD exacerbation rates at 52 weeks. The rate ratios favoured more exacerbations in ICS users who were current or heavier smokers than those who were ex-smokers or lighter smokers (0.81 to 0.99 vs 0.92 to 1.29).

Conclusions: In COPD, heavier or current smokers do not gain the same benefit from ICS use on lung function and exacerbation rates as lighter or ex-smokers do, however effects may not be clinically important.

Prospero Registration Number: CRD42019121833.

Citing Articles

A Delphi Consensus Project to Capture Greek Experts' Opinion on the Position of Triple Therapies in COPD: Why, When and to Whom.

Papaioannou A, Loukides S, Vassilakopoulos T, Tzanakis N, Kostikas K, Hillas G Int J Chron Obstruct Pulmon Dis. 2025; 20:457-471.

PMID: 40041472 PMC: 11878287. DOI: 10.2147/COPD.S481337.

Association of blood eosinophils with corticosteroid treatment failure stratified by smoking status among inpatients with AECOPD.

Li J, Zuo Y, Feng L, Samuel Cai Y, Su J, Tong Z BMJ Open Respir Res. 2024; 11(1).

PMID: 38609180 PMC: 11029211. DOI: 10.1136/bmjresp-2023-001634.

Analysis of Key Genes and miRNA-mRNA Networks Associated with Glucocorticoids Treatment in Chronic Obstructive Pulmonary Disease.

Wu J, Zhang P, Chen M, Zhang Y, Du W, Li X Int J Chron Obstruct Pulmon Dis. 2024; 19:589-605.

PMID: 38435123 PMC: 10909375. DOI: 10.2147/COPD.S441716.

Current smoking reduces small airway eosinophil counts in COPD.

Beech A, Booth S, Higham A, Singh D ERJ Open Res. 2024; 10(1).

PMID: 38259811 PMC: 10801758. DOI: 10.1183/23120541.00870-2023.

Clinical factors linked to the type of respiratory medication in COPD: results from the COSYCONET cohort.

Alter P, Kahnert K, Trudzinski F, Bals R, Watz H, Speicher T Ther Adv Respir Dis. 2023; 17:17534666231208584.

PMID: 37936408 PMC: 10631320. DOI: 10.1177/17534666231208584.

References

Barnes P, Ito K, Adcock I . Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet. 2004; 363(9410):731-3. DOI: 10.1016/S0140-6736(04)15650-X. View

Culpitt S, Rogers D, Shah P, De Matos C, Russell R, Donnelly L . Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002; 167(1):24-31. DOI: 10.1164/rccm.200204-298OC. View

Ito K, Hanazawa T, Tomita K, Barnes P, Adcock I . Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. Biochem Biophys Res Commun. 2004; 315(1):240-5. DOI: 10.1016/j.bbrc.2004.01.046. View

Hinds D, DiSantostefano R, Le H, Pascoe S . Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis. BMJ Open. 2016; 6(6):e010099. PMC: 4893846. DOI: 10.1136/bmjopen-2015-010099. View

Dransfield M, Bourbeau J, Jones P, Hanania N, Mahler D, Vestbo J . Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2014; 1(3):210-23. DOI: 10.1016/S2213-2600(13)70040-7. View

Marwick J, Caramori G, Stevenson C, Casolari P, Jazrawi E, Barnes P . Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med. 2009; 179(7):542-8. DOI: 10.1164/rccm.200810-1570OC. View

Burge P, Calverley P, Jones P, Spencer S, ANDERSON J, Maslen T . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000; 320(7245):1297-303. PMC: 27372. DOI: 10.1136/bmj.320.7245.1297. View

Zheng J, Yang L, Wu Y, Chen P, Wen Z, Huang W . The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD. Chest. 2007; 132(6):1756-63. DOI: 10.1378/chest.06-3009. View

Anthonisen N, Connett J, Murray R . Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002; 166(5):675-9. DOI: 10.1164/rccm.2112096. View

10.

Pauwels R, Lofdahl C, Laitinen L, Schouten J, Postma D, Pride N . Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999; 340(25):1948-53. DOI: 10.1056/NEJM199906243402503. View

11.

Bafadhel M, Peterson S, De Blas M, Calverley P, Rennard S, Richter K . Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018; 6(2):117-126. DOI: 10.1016/S2213-2600(18)30006-7. View

12.

Snoeck-Stroband J, Lapperre T, Sterk P, Hiemstra P, Thiadens H, Boezen H . Prediction of Long-Term Benefits of Inhaled Steroids by Phenotypic Markers in Moderate-to-Severe COPD: A Randomized Controlled Trial. PLoS One. 2015; 10(12):e0143793. PMC: 4699453. DOI: 10.1371/journal.pone.0143793. View

13.

Hoonhorst S, Ten Hacken N, Vonk J, Timens W, Hiemstra P, Lapperre T . Steroid resistance in COPD? Overlap and differential anti-inflammatory effects in smokers and ex-smokers. PLoS One. 2014; 9(2):e87443. PMC: 3914834. DOI: 10.1371/journal.pone.0087443. View

14.

Lamprecht B, McBurnie M, Vollmer W, Gudmundsson G, Welte T, Nizankowska-Mogilnicka E . COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest. 2010; 139(4):752-763. PMC: 3168866. DOI: 10.1378/chest.10-1253. View

15.

Vestbo J, Hurd S, Agusti A, Jones P, Vogelmeier C, Anzueto A . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2012; 187(4):347-65. DOI: 10.1164/rccm.201204-0596PP. View

16.

Invernizzi G, Ruprecht A, De Marco C, Mazza R, Nicolini G, Boffi R . Inhaled steroid/tobacco smoke particle interactions: a new light on steroid resistance. Respir Res. 2009; 10:48. PMC: 2703623. DOI: 10.1186/1465-9921-10-48. View

17.

Pascoe S, Barnes N, Brusselle G, Compton C, Criner G, Dransfield M . Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019; 7(9):745-756. DOI: 10.1016/S2213-2600(19)30190-0. View

18.

Suissa S, Barnes P . Inhaled corticosteroids in COPD: the case against. Eur Respir J. 2009; 34(1):13-6. DOI: 10.1183/09031936.00190908. View

19.

Wedzicha J, Banerji D, Chapman K, Vestbo J, Roche N, Ayers R . Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016; 374(23):2222-34. DOI: 10.1056/NEJMoa1516385. View

20.

Nowak D, Kasielski M, Antczak A, Pietras T, Bialasiewicz P . Increased content of thiobarbituric acid-reactive substances and hydrogen peroxide in the expired breath condensate of patients with stable chronic obstructive pulmonary disease: no significant effect of cigarette smoking. Respir Med. 1999; 93(6):389-96. DOI: 10.1053/rmed.1999.0574. View